SCHEMBL870320

SCHEMBL870320

O=C(Cc1ccccc1)N1CCc2cc(Br)ccc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.70
CYP11B1 P15538 1/20 0.61
CYP11B2 P19099 1/20 0.61
RAB9A P51151 5/20 0.53
MAPT P10636 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
POLB P06746 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
PIK3CD O00329 2/20 0.52
PIK3CB P42338 2/20 0.52
PTPN11 Q06124 1/20 0.52
KDM1A O60341 1/20 0.51
KDM1B Q8NB78 1/20 0.51
NPC1 O15118 4/20 0.50
NFKB1 P19838 2/20 0.50
NFKB2 Q00653 2/20 0.50
RELA Q04206 2/20 0.50
TSHR P16473 2/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL869113 0.86 RIPK1 (0.54) ALDH1A1CYP11B1CYP11B2RAB9ASMN1; SMN2
SCHEMBL869066 0.83 RIPK1 (0.55) ALDH1A1CYP11B1CYP11B2MAPTSMN1; SMN2
SCHEMBL14156333 0.83 ALDH1A1 (1.00) ALDH1A1RAB9AMAPTSMN1; SMN2POLB
SCHEMBL4630914 0.83 ALDH1A1 (0.72) ALDH1A1RAB9AMAPTSMN1; SMN2POLB
SCHEMBL4523961 0.81 HTR2C (0.58) ALDH1A1CYP11B1CYP11B2RAB9AMAPT
SCHEMBL31331181 0.81 NPC1 (0.72) ALDH1A1CYP11B1CYP11B2RAB9AMAPT
SCHEMBL18763042 0.80 SLC22A12 (0.58) ALDH1A1RAB9AMAPTSMN1; SMN2POLB
SCHEMBL19687695 0.80 CYP11B1 (0.56) ALDH1A1CYP11B1CYP11B2MAPTSMN1; SMN2
SCHEMBL4801009 0.80 HSD17B3 (0.69) ALDH1A1RAB9AMAPTSMN1; SMN2POLB
SCHEMBL288802 0.79 SLC22A12 (0.59) ALDH1A1PIK3CDPIK3CBNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017114510-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY, METHOD FOR PREPARATION THEREOF, AND USE THEREOF 中国科学院上海药物研究所 2017-07-06 WO disclosed
EP-2549868-B1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2015-01-07 EP disclosed
US-8598156-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2013-12-03 US disclosed
CN-102917588-A Chemical compounds GLAXOSMITHKLINE LLC 2013-02-06 CN disclosed
US-20130018038-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2013-01-17 US disclosed
US-8211919-B2 Amide derivatives as rock inhibitors ASTELLAS PHARMA INC. (JP) 2012-07-03 US disclosed
US-20120077828-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2012-03-29 US disclosed
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-04-23 US disclosed
CN-101253152-A Amide derivatives as ROCK inhibitors ASTELLAS PHARMA INC (JP) 2008-08-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018038-A1 CHEMICAL COMPOUNDS BRCA1, IRS1, IGF1R ALDH1A1 1192/4885CYP11B1 341/4885CYP11B2 1031/4885
US-20120077828-A1 CHEMICAL COMPOUNDS BRCA1, IRS1, IGF1R ALDH1A1 1192/4885CYP11B1 341/4885CYP11B2 1031/4885
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ROCK1, ROCK2, RHOA ALDH1A1 3985/4885CYP11B1 971/4885CYP11B2 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.